<p>Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - 獲取免費報告) 的股價在週二交易中下跌了 1.9%。該公司的股價最低曾達到 3.11 美元，最後交易價為 3.14 美元。在午間交易中，約有 325,694 股易手，較平均每日交易量 400,771 股下降了 19%。該股票此前收盤價為 3.20 美元。</p>
<p>獲取 <strong>Atea Pharmaceuticals</strong> 的提醒：</p>
<h2>華爾街分析師預測增長</h2>
<p>幾位股票分析師最近對 AVIR 股票發表了評論。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Atea Pharmaceuticals 的 “賣出（d-）” 評級。Evercore ISI 在 11 月 28 日的報告中將 Atea Pharmaceuticals 的評級上調至 “強力買入”。一位分析師給予該股票強力買入評級，一位給予買入評級，一位給予持有評級，還有一位給予賣出評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 6.00 美元。</p>
<p><strong>查看我們關於 Atea Pharmaceuticals 的最新報告</strong></p>
<h2>Atea Pharmaceuticals 股價下跌 1.9%</h2>
<p>該公司的 50 日簡單移動平均線為 3.13 美元，200 日簡單移動平均線為 3.28 美元。該公司的市值為 2.4533 億美元，市盈率為-1.77，貝塔值為 0.16。</p>
<p>Atea Pharmaceuticals (NASDAQ:AVIR - 獲取免費報告) 最近在 11 月 12 日發佈了其財報。該公司報告的每股收益（EPS）為-0.53 美元，低於分析師的共識預期-0.46 美元，差距為 0.07 美元。研究分析師平均預測 Atea Pharmaceuticals, Inc.在當前財年的每股收益將為-2.01 美元。</p>
<h2>對 Atea Pharmaceuticals 的對沖基金看法</h2>
<p>幾家對沖基金和其他機構投資者最近對 AVIR 的持倉進行了調整。Prudential Financial Inc.在第二季度購買了價值約 36,000 美元的 Atea Pharmaceuticals 新頭寸。Johnson Investment Counsel Inc.在第二季度收購了價值約 55,000 美元的 Atea Pharmaceuticals 新股份。BNP Paribas Financial Markets 在第三季度將其在 Atea Pharmaceuticals 的持股增加了 57.7%。BNP Paribas Financial Markets 目前擁有該公司 19,913 股股票，價值 58,000 美元，此前在該期間又購買了 7,286 股。SG Americas Securities LLC 在第三季度購買了價值約 59,000 美元的 Atea Pharmaceuticals 新股份。最後，Certified Advisory Corp 在第三季度收購了價值約 71,000 美元的 Atea Pharmaceuticals 新頭寸。機構投資者和對沖基金持有該公司 86.67% 的股份。</p>
<h2>Atea Pharmaceuticals 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Atea Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於為病毒感染患者發現、開發和商業化抗病毒治療。其主要產品候選藥物是 AT-527，一種口服抗病毒候選藥物，目前正在進行針對 COVID-19 患者的第三階段 SUNRISE-3 臨牀試驗。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票比 Atea Pharmaceuticals 更好</li>
<li>內部交易可能不會告訴你你想的那樣</li>
<li>消費者得到了煤炭，但聖誕老人給這兩家零售商帶來了巨大的收益</li>
<li>什麼是低市盈率，它對投資者意味着什麼？</li>
<li>10 倍收益？這三隻機器人股票可能在 2035 年前爆炸</li>
<li>最佳能源股票 - 現在值得購買的能源股票</li>
<li>安海斯 - 布希收購 BeatBox 以吸引年輕飲酒者</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Atea Pharmaceuticals 嗎？</h2>
<p>在你考慮 Atea Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Atea Pharmaceuticals 並不在名單上。</p>
<p>雖然 Atea Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

AVIR

<p>Atea Pharmaceuticals（納斯達克代碼：AVIR）股票下跌 1.9%，至 3.14 美元，交易量較平均水平下降 19%。分析師的評級各不相同：一項強烈買入、一項買入、一項持有和一項賣出，整體共識為適度買入，目標價格為 6.00 美元。該公司報告第三季度每股收益為（0.53 美元），未能達到預期。機構投資者持有 86.67% 的股份。Atea 正在開發 AT-527，這是一種針對 COVID-19 的抗病毒藥物，目前處於第三階段試驗中</p>

<p>Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Get Free Report)'s stock price was down 1.9% during trading on Tuesday . The company traded as low as $3.11 and last traded at $3.14. Approximately 325,694 shares changed hands during mid-day trading, a decline of 19% from the average daily volume of 400,771 shares. The stock had previously closed at $3.20.</p>
<div class="lb-trans"><p>Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - 獲取免費報告) 的股價在週二交易中下跌了 1.9%。該公司的股價最低曾達到 3.11 美元，最後交易價為 3.14 美元。在午間交易中，約有 325,694 股易手，較平均每日交易量 400,771 股下降了 19%。該股票此前收盤價為 3.20 美元。</p>
</div><p>Get <strong>Atea Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Atea Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several equities analysts recently commented on AVIR shares. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Atea Pharmaceuticals in a research note on Wednesday, October 8th. Evercore ISI upgraded Atea Pharmaceuticals to a &#34;strong-buy&#34; rating in a report on Friday, November 28th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $6.00.</p>
<div class="lb-trans"><p>幾位股票分析師最近對 AVIR 股票發表了評論。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Atea Pharmaceuticals 的 “賣出（d-）” 評級。Evercore ISI 在 11 月 28 日的報告中將 Atea Pharmaceuticals 的評級上調至 “強力買入”。一位分析師給予該股票強力買入評級，一位給予買入評級，一位給予持有評級，還有一位給予賣出評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 6.00 美元。</p>
</div><p><strong>View Our Latest Report on Atea Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Atea Pharmaceuticals 的最新報告</strong></p>
</div><h2>Atea Pharmaceuticals Stock Down 1.9%</h2>
<div class="lb-trans"><h2>Atea Pharmaceuticals 股價下跌 1.9%</h2>
</div><p>The company has a 50 day simple moving average of $3.13 and a 200 day simple moving average of $3.28. The company has a market capitalization of $245.33 million, a price-to-earnings ratio of -1.77 and a beta of 0.16.</p>
<div class="lb-trans"><p>該公司的 50 日簡單移動平均線為 3.13 美元，200 日簡單移動平均線為 3.28 美元。該公司的市值為 2.4533 億美元，市盈率為-1.77，貝塔值為 0.16。</p>
</div><p>Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last issued its earnings results on Wednesday, November 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.07). On average, research analysts forecast that Atea Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Atea Pharmaceuticals (NASDAQ:AVIR - 獲取免費報告) 最近在 11 月 12 日發佈了其財報。該公司報告的每股收益（EPS）為-0.53 美元，低於分析師的共識預期-0.46 美元，差距為 0.07 美元。研究分析師平均預測 Atea Pharmaceuticals, Inc.在當前財年的每股收益將為-2.01 美元。</p>
</div><h2>Hedge Funds Weigh In On Atea Pharmaceuticals</h2>
<div class="lb-trans"><h2>對 Atea Pharmaceuticals 的對沖基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in AVIR. Prudential Financial Inc. purchased a new position in Atea Pharmaceuticals in the second quarter valued at about $36,000. Johnson Investment Counsel Inc. acquired a new stake in shares of Atea Pharmaceuticals in the second quarter valued at about $55,000. BNP Paribas Financial Markets raised its holdings in shares of Atea Pharmaceuticals by 57.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 19,913 shares of the company's stock valued at $58,000 after buying an additional 7,286 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Atea Pharmaceuticals during the 3rd quarter valued at about $59,000. Finally, Certified Advisory Corp acquired a new position in Atea Pharmaceuticals during the 3rd quarter worth approximately $71,000. Institutional investors and hedge funds own 86.67% of the company's stock.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近對 AVIR 的持倉進行了調整。Prudential Financial Inc.在第二季度購買了價值約 36,000 美元的 Atea Pharmaceuticals 新頭寸。Johnson Investment Counsel Inc.在第二季度收購了價值約 55,000 美元的 Atea Pharmaceuticals 新股份。BNP Paribas Financial Markets 在第三季度將其在 Atea Pharmaceuticals 的持股增加了 57.7%。BNP Paribas Financial Markets 目前擁有該公司 19,913 股股票，價值 58,000 美元，此前在該期間又購買了 7,286 股。SG Americas Securities LLC 在第三季度購買了價值約 59,000 美元的 Atea Pharmaceuticals 新股份。最後，Certified Advisory Corp 在第三季度收購了價值約 71,000 美元的 Atea Pharmaceuticals 新頭寸。機構投資者和對沖基金持有該公司 86.67% 的股份。</p>
</div><h2>Atea Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Atea Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.</p>
<div class="lb-trans"><p>Atea Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於為病毒感染患者發現、開發和商業化抗病毒治療。其主要產品候選藥物是 AT-527，一種口服抗病毒候選藥物，目前正在進行針對 COVID-19 患者的第三階段 SUNRISE-3 臨牀試驗。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Atea Pharmaceuticals</li>
<li>Insider Trades May Not Tell You What You Think</li>
<li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li>
<li>What is a Low P/E Ratio and What Does it Tell Investors?</li>
<li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li>
<li>Best Energy Stocks - Energy Stocks to Buy Now</li>
<li>Anheuser-Busch Buys BeatBox to Win Over Younger Drinkers</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Atea Pharmaceuticals 更好</li>
<li>內部交易可能不會告訴你你想的那樣</li>
<li>消費者得到了煤炭，但聖誕老人給這兩家零售商帶來了巨大的收益</li>
<li>什麼是低市盈率，它對投資者意味着什麼？</li>
<li>10 倍收益？這三隻機器人股票可能在 2035 年前爆炸</li>
<li>最佳能源股票 - 現在值得購買的能源股票</li>
<li>安海斯 - 布希收購 BeatBox 以吸引年輕飲酒者</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Atea Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Atea Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Atea Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Atea Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atea Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Atea Pharmaceuticals 並不在名單上。</p>
</div><p>While Atea Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Atea Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Atea Pharmaceuticals（NASDAQ:AVIR）股價下跌 1.9% - 你是否應該賣出？